Human Immunodeficiency VirusSmoking CessationSmoking, Tobacco
Investigational drug(s) / intervention(s)
VareniclinePositively Smoke Free Mobile (PSF-M)Standard Care
Varenicline: Per package dosing, tablet taken orally
Positively Smoke Free Mobile (PSF-M): Behavioral tobacco cessation intervention for people living with HIV, delivered via mobile phone
Standard Care: Brief cessation advice plus referral to local tobacco quitline
Study summary
The goal of this research study is to test an intervention to help quit tobacco use in participants with Human Immunodeficiency Virus (HIV).
The study interventions used in this research study are:
* Positively Smoke Free - Mobile (PSF-M) (mobile behavioral program)
* Varenicline (or Chantix, apovarenicline, Champix or Nocrav)
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Adults (≥18 years)
* Confirmed HIV diagnosis
* Self-reported current smoking or dual tobacco use verified either by exhaled carbon monoxide ≥7 ppm, or by positive qualitative cotinine point-of-care test
* Able to read at 6th grade level or greater and speak Tamil, Telugu or English
* Able to use varenicline safely based on evaluation by primary provider at VHS
* Women of childbearing potential who consent to use a medically approved method of contraception or abstain from intercourse while taking study medication and for one month after.
* Ready to quit or interested in quitting
Exclusion Criteria:
* Pregnant or planning to become pregnant in the next 6 months
* Breastfeeding
* Myocardial infarction in past 30 days or unstable angina
* History of liver or kidney failure
* Alanine aminotransferase and Aspartate aminotransferase \> 2 times upper limit of normal or creatinine clearance \<50 in past 6 months
* History of suicide attempt
* Current suicidal ideation
* Untreated or unstable major depressive disorder
* History of psychosis or on anti-psychotic medications
* Cognitive impairment limiting ability to consent
* Allergy to varenicline
Primary outcome measure(s)
7-Day Point Prevalent Abstinence Rate — 24 weeks post-randomization Defined as abstinence from all combustible and smokeless tobacco products in the 7 days preceding 24-week follow-up supported by a negative urine cotinine test of \< 50 ng/ml
Trial sites (2)
Facility
City
Region
Status
University of Colorado
Aurora
Colorado
Recruiting
VHS Infectious Disease Medical Centre, CART Clinical Research Site
Chennai
Tamil Nadu
Recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.